

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
INTENDED AUDIENCE.....	2
SCOPE OF REPORT	2
INFORMATION SOURCES.....	3
ANALYST CREDENTIALS.....	3
RELATED REPORTS.....	3
BCC ON-LINE SERVICES.....	4
DISCLAIMER	4
CHAPTER TWO: SUMMARY.....	5
<i>SUMMARY TABLE GLOBAL SALES OF THERAPEUTIC</i>	
<i>MONOCLONAL ANTIBODIES, THROUGH 2016 (\$ MILLIONS)</i>	5
<i>SUMMARY FIGURE GLOBAL SALES OF THERAPEUTIC</i>	
<i>MONOCLONAL ANTIBODIES, 2009-2016 (\$ MILLIONS)</i>	6
CHAPTER THREE: OVERVIEW	7
DEFINITIONS	7
DEFINITIONS (CONTINUED).....	8
THE IMPORTANCE OF ANTIBODY DRUGS AND DIAGNOSTICS	9
THE IMPORTANCE OF ANTIBODY ... (CONTINUED).....	10
INTELLECTUAL PROPERTY ISSUES AND PATENT LICENSING	11
THE HISTORY OF THE COMMERCIALIZATION OF	
MONOCLONAL ANTIBODY PRODUCTS	11
<i>TABLE 1 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL</i>	
<i>ANTIBODY PRODUCTS</i>	11
ADVANTAGES OF MONOCLONAL ANTIBODY DRUGS.....	12
WHY DO MONOCLONAL ANTIBODY PRODUCTS HAVE SO MANY	
APPLICATIONS COMPARED WITH POLYCLONAL ANTIBODY	
PRODUCTS?.....	13
VALUATION OF ANTIBODY PRODUCT SALES	14
CHAPTER FOUR: TECHNOLOGY AND TECHNICAL ISSUES	15
OVERVIEW.....	15
OVERVIEW (CONTINUED)	16
<i>TABLE 2 MONOCLONAL ANTIBODIES VERSUS SMALL MOLECULE</i>	
<i>DRUGS</i>	17
<i>TABLE 2 (CONTINUED)</i>	18
<i>TABLE 3 MONOCLONAL ANTIBODIES VERSUS POLYCLONAL</i>	
<i>ANTIBODIES</i>	18
THE HAMA PROBLEM AND ITS RESOLUTION	19
PHAGE DISPLAY AND POLYSOME DISPLAY	20
PHAGE DISPLAY AND POLYSOME ... (CONTINUED).....	21

DIRECTED EVOLUTION.....	22
ANTIBODY CLASSES.....	22
<i>TABLE 4 ANTIBODY TYPES AND DESCRIPTIONS.....</i>	<i>23</i>
ANTIBODY FORMS IN PRODUCTS.....	23
<i>TABLE 5 GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES BY ANTIBODY TECHNOLOGY TYPE, THROUGH 2016 (\$ MILLIONS).....</i>	<i>24</i>
<i>TABLE 6 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY ANTIBODY FORM (NUMBER/%).....</i>	<i>25</i>
<i>TABLE 7 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY TECHNOLOGY FORM AND STAGE OF DEVELOPMENT.....</i>	<i>25</i>
<i>TABLE 8 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY TARGET.....</i>	<i>26</i>
ABTIDES.....	26
ANTIBODY-DRUG CONJUGATES / IMMUNOCONJUGATES.....	26
ANTISERUMS.....	27
BISPECIFIC ANTIBODIES.....	28
CAMOUFLAGED ANTIBODIES.....	28
CHIMERIC ANTIBODIES.....	29
HUMANIZED ANTIBODIES.....	29
Humanized Antibodies (Continued).....	30
FULLY HUMAN ANTIBODIES.....	31
PROGENITOR STEM CELLS.....	32
SINGLE-CHAIN ANTIBODIES.....	32
SYNTHETIC ANTIBODIES.....	33
SOURCES OF MONOCLONAL ANTIBODIES ON THE MARKET.....	34
<i>TABLE 9 MARKETED MONOCLONAL ANTIBODY PRODUCTS AND THEIR SOURCES.....</i>	<i>34</i>
<i>TABLE 9 (CONTINUED).....</i>	<i>35</i>
<i>TABLE 9 (CONTINUED).....</i>	<i>36</i>
THE SPECIAL CASE OF ENBREL.....	36
ANTIBODY TECHNOLOGIES IN DEVELOPMENT.....	37
AFFIBODIES.....	37
DOMAIN ANTIBODIES.....	37
NANOBODIES.....	38
<i>TABLE 10 MONOCLONAL ANTIBODIES IN PHASE 3 DEVELOPMENT.....</i>	<i>39</i>
<i>TABLE 10 (CONTINUED).....</i>	<i>40</i>
<i>TABLE 11 MONOCLONAL ANTIBODIES IN PHASE 2 DEVELOPMENT.....</i>	<i>40</i>
<i>TABLE 11 (CONTINUED).....</i>	<i>41</i>
<i>TABLE 11 (CONTINUED).....</i>	<i>42</i>
<i>TABLE 11 (CONTINUED).....</i>	<i>43</i>
<i>TABLE 11 (CONTINUED).....</i>	<i>44</i>
<i>TABLE 11 (CONTINUED).....</i>	<i>45</i>
<i>TABLE 11 (CONTINUED).....</i>	<i>46</i>

<i>TABLE 11 (CONTINUED)</i>	47
<i>TABLE 12 MONOCLONAL ANTIBODIES IN PHASE 1 DEVELOPMENT</i>	47
<i>TABLE 12 (CONTINUED)</i>	48
<i>TABLE 12 (CONTINUED)</i>	49
<i>TABLE 12 (CONTINUED)</i>	50
<i>TABLE 12 (CONTINUED)</i>	51
<i>TABLE 12 (CONTINUED)</i>	52
NEW DIRECTIONS IN ANTIBODY RESEARCH.....	53
THE MARKET OPPORTUNITY FOR TRANSGENIC PRODUCTION OF ANTIBODY PRODUCTS	53
THE MARKET OPPORTUNITY FOR ... (CONTINUED).....	54
THE HIGH COST OF PRODUCING ANTIBODIES AND OTHER PROTEIN DRUGS.....	55
THE GROWING CRISIS IN MEETING PRODUCTION DEMANDS FOR PROTEIN DRUGS	56
THE TRANSGENIC ADVANTAGE.....	56
TRADITIONAL PRODUCTION METHODS	57
MICROBIAL FERMENTATION	58
MAMMALIAN CELL CULTURE.....	58
THE ENBREL SHORTAGE.....	59
THE CRUNCH IN CAPACITY.....	59
REASONS FOR THE NEED TO INCREASE PROTEIN DRUG PRODUCTION	60
GENOMICS AND GENE DISCOVERY DRIVE THE EXPANDING DEVELOPMENT OF PROTEIN DRUGS	61
PRODUCTION OF ANTIBODIES IN ANIMALS	62
PRODUCTION OF ANTIBODIES ... (CONTINUED).....	63
GOATS AS MONOCLONAL ANTIBODIES FACTORIES	64
PRODUCTION OF ANTIBODIES IN PLANTS.....	64
PLASTIDS	64
TARGETING AND COMPARTMENTALIZING	65
TRANSGENIC SEEDS FOR ANTIBODY STORAGE.....	65
CHAPTER FIVE: PRODUCTS	66
OVERVIEW.....	66
MARKETED PRODUCTS	66
<i>TABLE 13 GLOBAL SALES OF MONOCLONAL ANTIBODIES, BY PRODUCT THROUGH 2016 (\$ MILLIONS)</i>	67
<i>TABLE 14 U.S. SALES OF MONOCLONAL ANTIBODIES, BY PRODUCT THROUGH 2016 (\$ MILLIONS)</i>	68
<i>TABLE 15 REST OF WORLD SALES OF MONOCLONAL ANTIBODIES, BY PRODUCT THROUGH 2016 (\$ MILLIONS)</i>	69
GEMTUZUMAB OZOGAMICIN (MYLOTARG)	70
DACLIZUMAB (ZENAPAX)	71
Daclizumab (Zenapax) (Continued)	72

<i>TABLE 16 DACLIZUMAB CHOICE STUDY RESULTS</i>	73
CATUMAXOMAB (REMOVAB)	74
TOCILIZUMAB (ACTEMRA, ROACTEMRA, RG1569).....	75
TRASTUZUMAB (HERCEPTIN, RG597).....	76
Trastuzumab (Herceptin, RG597) (Continued)	77
BEVACLIZUMAB (AVASTIN, RG435).....	78
Bevacizumab (Avastin, RG435) (Continued).....	79
Beverizumab (Avastin, RG435) (Continued).....	80
CETUXIMAB (ERBITUX)	81
Cetuximab (Erbix) (Continued)	82
PANITUMUMAB (VECTIBIX).....	83
Panitumumab (Vectibix) (Continued).....	84
IBRITUMOMAB TIUXETAN (ZEVALIN).....	85
Results of Trials.....	86
Sales of Zevalin.....	87
ALEMTUZUMAB (LEMTRADA, CAMPATH, MABCAMPATH)	88
Alemtuzumab (... (Continued)	89
Alemtuzumab (... (Continued)	90
NATALIZUMAB (TYSABRI)	91
<i>TABLE 17 TYSABRI SENTINEL AND AFFIRM STUDY RESULTS</i>	92
Natalizumab (Tysabri) (Continued).....	93
TOSITUMOMAB-I (BEXXAR)	94
Tositumomab-I (Bexxar) (Continued)	95
OFATUMUMAB (ARZERRA).....	96
Ofatumumab (Arzerra) (Continued)	97
RITUXIMAB (RITUXAN, MABTHERA, RG105)	98
INFLIXIMAB (REMICADE).....	99
Infliximab (Remicade) (Continued).....	100
DENOSUMAB (PROLIA, XGEVA)	101
IPILIMUMAB (YERVOY, MDX-010)	102
ADALIMUMAB (HUMIRA).....	103
GOLIMUMAB (SIMPONI)	104
CANAKINUMAB (ILARIS, ACZ885)	105
ECULIZUMAB (SOLIRIS).....	106
PALIVIZUMAB (SYNAGIS)	107
ABCIXIMAB (REOPRO).....	108
Abciximab (ReoPro) (Continued).....	109
Abciximab (ReoPro) (Continued).....	110
RANIBIZUMAB (LUCENTIS).....	111
Ranibizumab (Lucentis) (Continued).....	112
MUROMONAB (ORTHOCLONE OKT3).....	113
OMALIZUMAB (XOLAIR)	113
USTEKINUMAB (STELARA, CNTO 1275).....	114
Ustekinumab (Stelara, CNTO 1275) (Continued).....	115

CERTOLIZUMAB PEGOL (CIMZIA)	116
BASILIXIMAB (SIMULECT)	116
Basiliximab (Simulect) (Continued).....	117
BELIMUMAB (BENLYSTA)	118
NIMOTUZUMAB	119
PRODUCTS IN DEVELOPMENT	119
TANEZUMAB (RN624).....	119
VEDOLIZUMAB (MLN0002).....	120
LY2127399.....	121
OTELIXIZUMAB	121
MEPOLIZUMAB (BOSATRIA).....	122
TEPLIZUMAB (MGA031, HOKT3-GAMMA1)	122
BAPINEUZUMAB (AAB-001)	123
GANITUMAB (AMG 479).....	124
OBINUTUZUMAB (AFUTUZUMAB, GA101, RG7159)	125
ZANOLIMUMAB (FORMERLY HUMAX-CD4)	126
RESLIZUMAB (CINQUIL)	127
BLINATUMOMAB (MT103).....	128
FARLETUZUMAB (MORAB-003).....	128
EPRATUZUMAB.....	129
GIRENTUXIMAB (RENCAREX)	129
INOTUZUMAB OZOGAMICIN (CMC-544).....	130
BRIKINUMAB (ABT-874).....	131
ELOTUZUMAB.....	132
SILTUXIMAB (CNTO 328).....	133
TRASTUZUMAB EMTANSINE (T-DM1, RG3502).....	133
INOLIMOMAB (LEUKOTAC).....	134
ITOLIZUMAB (T1H, ANTI-CD6)	134
NAPTUMOMAB ESTAFENATOX (ANYARA)	135
NECITUMUMAB (IMC-11F8).....	135
PERTUZUMAB	136
RAMUCIRUMAB (IMC-1121B, LY3009806).....	137
RAXIBACUMAB	138
MK-3415, MK-6072, AND MK-3415A	138
MK-3415, MK-6072, and MK-3415A (Continued).....	139
CHAPTER SIX: APPLICATIONS.....	140
OVERVIEW.....	140
TABLE 18 MONOCLONAL ANTIBODIES ON THE MARKET, BY INDICATION 2011 (NUMBER/%).....	140
TABLE 19 GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, BY APPLICATION, THROUGH 2016 (\$ MILLIONS).....	141
TABLE 20 MONOCLONAL ANTIBODIES IN CLINICAL STAGE DEVELOPMENT, BY INDICATION, 2011 (NUMBER/%).....	141
TABLE 20 (CONTINUED).....	142

AUTOIMMUNE DISEASES	142
CROHN'S DISEASE	143
PSORIASIS.....	144
RHEUMATOID ARTHRITIS.....	145
<i>TABLE 21 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF INFLAMMATORY DISEASES (NOT INCLUDING MS), THROUGH 2016 (\$ MILLIONS).....</i>	<i>145</i>
SOLID TUMORS	146
U.S. CANCER STATISTICS.....	146
<i>TABLE 22 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2011</i>	<i>147</i>
<i>TABLE 23 CANCER PREVALENCE RATES IN THE U.S., 2008 (IN THOUSANDS)</i>	<i>148</i>
BREAST CANCER.....	149
COLORECTAL CANCER	149
HEAD AND NECK CANCER.....	149
KIDNEY CANCER.....	149
LIVER CANCER	149
LUNG CANCER.....	150
MALIGNANT MELANOMA.....	150
OSTEOSARCOMA	151
OVARIAN CANCER	151
PANCREATIC CANCER	152
PROSTATE CANCER	152
STOMACH CANCER.....	153
ANTIBODY PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER.....	153
<i>TABLE 24 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF SOLID TUMORS, BY REGION, THROUGH 2016 (\$ MILLIONS).....</i>	<i>153</i>
LYMPHOMAS AND LEUKEMIAS.....	153
NON-HODGKIN LYMPHOMA.....	154
LEUKEMIAS.....	154
Leukemias (Continued)	155
CARDIOVASCULAR DISEASES	156
PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY	157
INFECTIOUS DISEASES.....	158
CYTOMEGALOVIRUS INFECTION.....	159
HEPATITIS	160
RESPIRATORY SYNCYTIAL VIRUS INFECTION	160
<i>TABLE 25 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF INFECTIOUS DISEASES, BY REGION, THROUGH 2016 (\$ MILLIONS).....</i>	<i>161</i>

MULTIPLE SCLEROSIS	161
<i>TABLE 26 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF MULTIPLE SCLEROSIS, BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	162
OPHTHALMIC DISEASES.....	162
MACULAR DEGENERATION.....	162
OTHER THERAPEUTIC APPLICATIONS.....	163
<i>TABLE 27 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF OTHER DISEASES, BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	163
CHAPTER SEVEN: INDUSTRY STRUCTURE	164
OVERVIEW.....	164
ORIGINATORS.....	164
COMMERCIAL DEVELOPERS.....	165
VENDORS.....	166
MANUFACTURERS.....	166
TECHNOLOGY INNOVATORS.....	167
PRICING FORECASTS.....	168
THE REGULATORY ENVIRONMENT	168
THE REGULATORY ENVIRONMENT (CONTINUED).....	169
GENOMICS AND MONOCLONAL ANTIBODIES: A MATCH FOR SUCCESS.....	170
GENOMICS AND MONOCLONAL ... (CONTINUED).....	171
GENOMICS AND MONOCLONAL ... (CONTINUED).....	172
COMPANY SALES AND MARKET SHARE.....	173
<i>TABLE 28 SALES OF MARKETED ANTIBODIES BY MANUFACTURER, THROUGH 2016 (\$ MILLIONS)</i>	174
<i>TABLE 29 MANUFACTURERS OF ANTIBODIES BY MARKET SHARE, 2011 AND 2016 (%)</i>	175
<i>TABLE 30 MONOCLONAL ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY COMPANY</i>	176
COMPANY PROFILES	176
ABBOTT LABORATORIES.....	176
ALEXION PHARMACEUTICALS	177
AMGEN	178
ASTRAZENECA.....	179
AstraZeneca – U.S. Headquarters	179
BAYER AG	180
Bayer (U.S. Location)	180
BIOGEN IDEC	181
BRISTOL-MYERS SQUIBB	182
BTG.....	183
DAIICHI SANKYO.....	183
ELAN	184

EMERGENT BIOSOLUTIONS.....	185
EISAI	185
ELI LILLY	186
GENMAB.....	186
Genmab (U.S. Location)	187
GLAXOSMITHKLINE	187
GlaxoSmithKline (U.S. Location).....	187
HUMAN GENOME SCIENCES.....	188
JOHNSON & JOHNSON.....	188
KALOBIOS PHARMACEUTICALS.....	189
MERCK KGAA (MERCK SERONO).....	190
MORPHOSYS.....	191
NOVARTIS	191
PFIZER	192
ROCHE	193